🎥 Can non thermal plasma seed treatment move from lab curiosity to broadacre reality?
[Disclosure: AgFunderNews’ parent company AgFunder is an investor in Sylvarum] Using non-thermal plasma or high voltage …
FDA Issues Proposal to Streamline Registration for Advanced Distributed Manufacturers
The FDA states that its newly proposed rule, if finalized, would create a streamlined registration pathway for distributed manufacturing establishments that operate as a single establishment using a “hub-and-spoke” model. The proposed rule would also clarify registration requirements for certain foreign establishments that manufacture drugs, including active pharmaceutical ingredients (APIs), that indirectly enter the U.S. drug supply.
🎥 Inside Faraday Earth’s bid to make cheap green ammonia without Haber-Bosch
[Disclosure: AgFunderNews’ parent company AgFunder is an investor in Faraday Earth] Can a container-sized plasma reactor…
🎥 Can non thermal plasma seed treatment move from lab curiosity to broadacre reality?
[Disclosure: AgFunderNews’ parent company AgFunder is an investor in Sylvarum] Using non-thermal plasma or high voltage …
🎥 Inside Faraday Earth’s bid to make cheap green ammonia without Haber-Bosch
[Disclosure: AgFunderNews’ parent company AgFunder is an investor in Faraday Earth] Can a container-sized plasma reactor…
🎥 Can non thermal plasma seed treatment move from lab curiosity to broadacre reality?
[Disclosure: AgFunderNews’ parent company AgFunder is an investor in Sylvarum] Using non-thermal plasma or high voltage …
新型农药产品出海的隐形专利雷区：以氟唑菌酰胺、砜吡草唑为例
以下内容整理自作者在 CPEW 2026 上的主题报告
在全球农药产业格局深刻重塑的背景下，中国农药企业的″出海″征程已从产品竞争转向以知识产权和合规管理为核心的系统性竞争。本文以氟唑菌酰胺、砜吡草唑等热门产品为切入点，深入剖析农药出海面临的专利侵权、样品管控与登记合规三大″隐形雷区″。
Late Rains, Tight Windows Challenge Weed Control In Kansas Row Crops
July 2026, Manhattan: Heavy rains and fast-growing crops are tightening the window for effective herbicide applications …
Report card from California: Farmers and investors need more education on ag biologicals
The ag biologicals sector is still making “steady progress” in terms of new products and overall growth, Dr.…
WuXi AppTec bets on expansion in Europe
WuXi AppTec, the Chinese life sciences services company, is one of the world’s largest providers of research, development, and manufacturing services (CRDMO) for the pharmaceutical and biotechnology industries. The company supports customers across the entire value chain – from early drug discovery through preclinical and clinical development to commercial manufacturing. A science-driven organization, WuXi AppTec has built an international footprint through strategic acquisitions. Its protein design center in Gräfelfing, near Munich, is now being developed into the company’s European center of excellence for drug discovery. We spoke with Steve Yang, PhD, Co-CEO of WuXi AppTec.